Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 50
- Registration Number
- NCT02215993
- Locations
- 🇧🇷
Federal University of São Paulo, São Paulo, Brazil
TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization
- Conditions
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 59
- Registration Number
- NCT02211066
- Locations
- 🇪🇸
Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI
- Conditions
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 444
- Registration Number
- NCT02201667
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT02201771
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Nan Jing First Hospital, Nanjing, Jiangsu, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Hull University Teaching Hospitals NHS Trust
- Target Recruit Count
- 74
- Registration Number
- NCT02169596
- Locations
- 🇬🇧
Castle Hill Hospital (Hull and east Yorkshire Hospitals NHS Trust), Cottingham, East Yorkshire, United Kingdom
ONSET and OFFSET of Ticagrelor in ESRD
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Kyunghee University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02163954
- Locations
- 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of
Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2018-03-21
- Target Recruit Count
- 352
- Registration Number
- NCT02140801
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Jinan Central Hospital
- Target Recruit Count
- 350
- Registration Number
- NCT02123004
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan Shi, Shandong, China
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02121288
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2014-04-22
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 89
- Registration Number
- NCT02120092
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.